Q-Med's Second Gamble

Q-Med is looking to solve two big problems of the disease management business: creating a proprietary hook and selling cost-benefit results to managed care plans which fit within their very short time horizons. The company believes and has evidence that their coronary artery disease monitor can identify patients who will have a heart attack or require some serious medical intervention within the one-to two year time frame of managed care plans.

Disease management is a distinctly unproprietary business; different disease management companies can easily steal each other’s ideas along with their patients. Moreover, as attractive an opportunity as it appears—proper disease management can save billions by preventing overutilization of medical services—managed care companies haven’t really embraced it to its full potential.

The problem: apart from a few high-cost diseases, like asthma and diabetes, disease management costs a plan more in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By 

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Deals In Depth: July 2025

 
• By 

Six $1bn+ alliances were penned in July, and two exceeded $2bn.

Execs On The Move: July 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.